Health Highlights: Jan. 13, 2017Last Updated: January 13, 2017.
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
CVS Cuts Price of Generic Competitor to EpiPen
A generic competitor to Mylan's EpiPen is now available at CVS for about one-sixth the price.
CVS will charge $109.99 for a two-pack of the generic version of Adrenaclick, a lesser-known treatment than EpiPen, which can cost more than $600, the Associated Press reported.
The products are auto-injectors that contain the hormone epinephrine and provide emergency treatment for potentially deadly allergic reactions to foods such as nuts and eggs and to insect bites and stings.
The drug store chain said it cut the price of the generic version of Adrenaclick nearly in half and that the lower price is available in all its stores. The new price applies to both insured patients and those who pay cash without coverage, and is what customers will pay at the pharmacy counter, the AP reported.
Mylan has faced severe criticism for increasing the price of its EpiPen by more than 500 percent since 2007. The company introduced a generic product in December, which costs $300 for a two-pack.
Jessica Alba's Honest Company Recalls Organic Baby Powder
Actress Jessica Alba's Honest Company is recalling Honest Company its Organic Baby Powder due to a possible health risk.
The baby powder may be contaminated with microorganisms, including some that can cause skin or eye infections.
The recalled products were sold in 4 oz containers and carry the UPC code 817810014529. Customers can return the recalled baby powder for a full refund, the company said.
For more information, U.S. consumers can call 1-888-688-8653 Monday Friday 5 a.m. to 5 p.m. Pacific Time, and Canadian consumers can call 1-888-532-0190 Monday Friday 5 a.m. to 5 p.m. Pacific Time.
|Previous: Health Tip: Cutting Out Caffeine?||Next: Study Questions ‘Fecal Transplant’ Treatment for Gut Infection|
Reader comments on this article are listed below. Review our comments policy.